G1 Therapeutics, Inc. (GTHX)

Market Cap	378.17M
Revenue (ttm)	58.20M -34.7%
Net Income	-44.77M
EPS	-0.86
Shares Out	52.89M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,251,945
Open	7.15
Previous Close	7.15
Day's Range	7.14 - 7.16
52-Week Range	1.08 - 7.19
Beta	1.68
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 30, 2024

About GTHX

G1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing Trilaciclib that is in Phase 3 clinical trial for 1L m...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 17, 2017
• Employees: 100
• Stock Exchange: NASDAQ
• Ticker Symbol: GTHX
• Website: https://www.g1therapeutics.com

Financial Performance

In 2023, G1 Therapeutics's revenue was $82.51 million, an increase of 60.84% compared to the previous year's $51.30 million. Losses were -$47.97 million, -67.49% less than in 2022.

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Jan 1, 2000

Data Sources Report a data error